Basic & Clinical Medicine ›› 2024, Vol. 44 ›› Issue (7): 1018-1022.doi: 10.16352/j.issn.1001-6325.2024.07.1018

• Clinical Sciences • Previous Articles     Next Articles

Comparison of adverse reactions and effects of IMRT combined with different chemotherapy regimens in patients with early stage esophageal squamous cell carcinoma

ZHANG Wei1, ZHANG Zhen1, LIU Dong1, JIANG Houzhou1, LIANG Wei2*   

  1. 1. Department of Radiotherapy Oncology, Taihe County People's Hospital, Fuyang 236600;
    2. Department of Radiotherapy,Anhui Medical University First Affiliated Hospital,Hefei 230000 China
  • Received:2024-02-26 Revised:2024-05-22 Online:2024-07-05 Published:2024-06-26
  • Contact: *1072653593@qq.com

Abstract: Objective To investigate the adverse reactions, short-term and long-term effects of DP(docetaxel+cisplatin) regimen and PF(cisplatin+5-fluorouracil) regimen combined with intensity modulated radiation therapy(IMRT)in patients with distant metastatic esophageal squamous carcinoma. Methods From January 2021 to June 2022, 96 patients with non-metastatic esophageal squamous carcinoma were randomly divided into 48 cases in Taihe County People′s Hospital of Fuyang City, Anhui province and 48 cases in control group. Which was treated with DP plus IMRT. The observation group was treated with PF plus IMRT. The occurrence of adverse reactions and the effect of both groups were compared. Results Compared with control group, the difference in the incidence of adverse reaction was not significant. The total effective rate was higher in the observation group than in that in control group (83.3% vs 62.5%, P<0.05). Overall survival, 1-year survival, 3-year survival in observation and in control group were 70.83% vs 50.00%, 79.36% vs 60.23% and 65.10% vs 35.52%. Long-term outcomes were observed and compared. The median survival time was 34.40 months in the observation group and 18.3 months in control group (P<0.05). Conclusions DP regimen combined with IMRT is more effective than PF regimen combined with IMRT in the treatment of patients with distant metastatic esophageal squamous carcinoma.

Key words: esophageal squamous cell carcinoma, distant metastasis, adverse reaction, short-term and long-term effect, concurrent chemoradiotherapy

CLC Number: